StemCell Therapy

Parenting and veterinary medicine may not seem like they always go hand in hand. The demands of the job conflict with kids activities or, during the current pandemic, virtual schooling. But some practitioners have found they can make things work as long as they throw out the notion that there can be balance. Instead, they see the situation more as work-life integration with ebbs and flows.

During the session Having It All: Parenthood and Veterinary Medicine on Aug. 20 at the AVMA Virtual Convention 2020, parentsfrom stepparents to adoptive parents and everything in betweenalong with those without children talked about their needs, wants, and suggestions for making the professional and the personal come together in a workable manner.

Dr. Caitlin Davis Ashlock, a small animal practitioner in Frankfort, Indiana, is stepmom to a 7-year-old, Spencer. She also is expecting a son. Her philosophy about being a stepparent is that love is love, and there is never too much of it.

One other thing that helped me in my stepparent journey was talking to my husband about what his expectations of me in this role are, Dr. Ashlock said. Talking about expectations helped me to manage my own expectations and not feel like I wasnt doing enough.

Dr. Jon Hornback is an equine practitioner in Simpsonville, Kentucky, with two children. He and his wife found out they were having their first child when he was entering his internship.

Someone once told him, No one works 24 hours a day, so when youre home, make the most of it.

More celebration needs to be shared with those who have chosen not to be parents. Those of us who were parents were so overwhelmed and couldnt put it together. They were there to help us. It takes a village of parents and nonparents, and being a vet unites all of us.

Dr. Maggie Canning, session moderator, Having It All: Parenthood and Veterinary Medicine

Instead of being on his phone or watching TV by himself, he makes a point to spend time with his kids when hes home. Dr. Hornback even incorporates the kids into his work sometimes.

If theres an emergency, well all jump in the car and get dessert afterward, he said. Its something we like to do as a family.

Dr. Kayla Lichlyter, a small animal veterinarian in southern Indiana, was found to have endocrine issues a few weeks before her wedding. She and her husband, Josh, have two children: Asher, 2, and Adrienne, a newborn, who were both adopted. Becoming a mother helped her learn to say no and set boundaries for herself.

Even though vet med and being a vet is a huge passion of mine, and I love the work I do, at the end of the day, its a job, and theres more to life than that, Dr. Lichlyter said. Thats important to realize: I can want more to my life than just being a vet. Wanting more for your life beyond veterinary medicine doesnt make you a bad veterinarian. And if Im going the extra mile and have a few late nights at work, that doesnt make me a bad mom, either.

Dr. Carissa Norquest, an oncology specialist in Ohio, is married with no kids. She said a number of residents see starting a family as an inconvenience or threat to their career. Ive seen friends who have wanted a kid and waited to finish their PhD who are now struggling to conceive or are considering in vitro protocols because they put their career first, and they do not feel it was appropriately discussed in our career path, she said.

Had her colleagues known more at the beginning, they might have harvested their eggs or engaged in proactive family planning.

Planning early for our future is a topic that needs to be discussed more in veterinary medicine, she said. We need to be more open about this because the consequences are not reversible.

Dr. Brandon Thornberry, who practices in St. Louis, has a 10-month-old son, and his wife, Michelle, is a veterinarian, too. His father is also a veterinarian, so he uniquely understood the demands of the profession from a young age.

My dad was there for me growing up, but there were also times when his patients needed him more. Maybe the net result over my childhood was a balance, but from my perspective, a perfect 50-50 balance is not realistically achievable. That is OK, he said. Sometimes your family or your patients will demand more from you. Family is always my priority, but this profession and lifestyle I have chosen cannot always achieve a 50-50 balance.

Rather than being frustrated that I do not have a balance, I try to seek and advocate for good work-life integration, which means adopting a mindset that recognizes it is OK for work and home life to overlap at times, and work or home life may demand more from me, respectively, in different seasons of life.

Dr. Maggie Canning, one of the sessions moderators, said after having a cesarean section, which she hadnt planned for, she harbored guilt partly because she didnt have trust in her doctor. Now, she says, she has more empathy for first-time puppy owners asking how many times they can bathe their dog.

She encourages other veterinarian parents to join social media groups, such as the AVMAs Early Career Online Community on Facebook. She added, More celebration needs to be shared with those who have chosen not to be parents. Those of us who were parents were so overwhelmed and couldnt put it together. They were there to help us. It takes a village of parents and nonparents, and being a vet unites all of us.

The rest is here:
It takes a village for veterinarian parents to make it work - American Veterinary Medical Association

Fort Collins, Colorado The Veterinary Medicine Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The Veterinary Medicine Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the Veterinary Medicine Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Veterinary medicine market garnered a revenue of USD 30.5 billion in the year 2019 globally and has been foreseen to yield USD 51.4 billion by the year 2027 at a compound annual growth (CAGR) of 5.6% over the forecast period.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=85118

Industry Veterinary Medicine Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

Vetiquinol S.A.

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=85118

The report provides comprehensive data on the Veterinary Medicine market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Veterinary Medicine Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Veterinary Medicine market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

Veterinary Medicine Market, By End-use (2016-2027)

Veterinary Medicine Market, By Mode of Delivery (2016-2027)

Veterinary Medicine Market, By Animal Type (2016-2027)

Veterinary Medicine Market, By Product (2016-2027)

Request customization of the report @https://reportsglobe.com/need-customization/?rid=85118

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Veterinary Medicine Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/veterinary-medicine-market/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read more:
Veterinary Medicine Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

Sundays virtual Vet Med Open House will be like no other, according to UI Class of 2022 members JULIE KLEIN, a member of the event committee, and JI PARK, president of the UI chapter of Veterinarians as One Inclusive Community for Empowerment.

They took pen to paper to explain in this week's Town Hall.

***

Why is it that we are so quick to reject new information when it challenges our long-held beliefs? This question has taken center stage in 2020, a year when new evidence of the global COVID-19 pandemic and of our countrys systemic racism confronts our beliefs about the world almost daily.

Students at the University of Illinois College of Veterinary Medicine think stereotypes are part of the answer to this question. Stereotypes present stubborn barriers to learning new information. Thats why this year we are devoting our annual Open House to breaking down stereotypes and busting myths about all things animal- and Vet Med-related. Old dogs can indeed learn new tricks.

As renewed protests against racial injustice swept across the country, Open House organizers decided to take action to address the lack of diversity in their chosen profession. With leadership from the UI student chapter of Veterinarians as One Inclusive Community for Empowerment, we chose the theme of Myth Busting for the annual open house, which had to be moved online to comply with pandemic guidelines.

We are out to smash the stereotype that veterinarians only look a certain way. We want to show that anyone can become a veterinarian and find a rewarding career path suited to their interests.

Although the gender balance in the U.S. veterinary profession has shifted from overwhelmingly male throughout most of the 20th century to majority female for the first time in 2009 and about 70 percent female today the profession remains 90 percent White, according to Bureau of Labor Statistics data in 2019.

Deeply ingrained stereotypes can be one of the hardest barriers to break down. The lack of underrepresented minority veterinarians to serve as role models reinforces the stereotype that people of color cant become veterinarians, thus the stereotype becomes a self-fulfilling prophecy.

Our open-house website features interviews with more than 30 veterinary professionals from a variety of backgrounds working in diverse practice areas. We want to prove that a veterinary degree is one of the most versatile degrees. You can even hear from a second-career veterinarian who started as a police officer and went on to become the director of our colleges Veterinary Teaching Hospital.

More importantly, we want to empower children and prospective students from underrepresented backgrounds by showing them role models they can relate to, including veterinarians of color and veterinarians in the LGBTQ+ community.

The theme of breaking down stereotypes extends throughout our virtual open house. We invited all 40-plus student teams that normally host a booth at the in-person open house to develop myth-busting content related to their topic. We cant wait for you to explore the thought-provoking information about wildlife, breeds, diseases, veterinary careers and much more when our website goes live Sunday. (RSVP on Facebook here: https://www.facebook.com/events/325561818663612/).

Busting stereotypes challenging long-held beliefs opens hearts and minds to a whole world of opportunities and experiences that were previously unexplored. Taking in new information is fundamental to growing as a person as well as growing as a society. We hope our open house will expose you to new information about animals and a profession you thought you already knew. You might even come away with a different perspective.

***

Every Tuesday and some Thursdays in The News-Gazette, well turn over our Commentary page to community members and other experts with local ties. If you have interest in weighing in on a topic making news, contact Editor Jeff D'Alessio at 217-393-8249 or jdalessio@news-gazette.com.

Continued here:
Guest Commentary | 'We are out to smash the stereotype that veterinarians only look a certain way' - Champaign/Urbana News-Gazette

Friday, October 2, 2020

The kick-off event for the 2020 virtual Purdue Veterinary Conference featured an intriguing look at the life of service dogs. Held Tuesday, September 22, the Elanco Human-Animal Bond Lecture featured a Zoom presentation by Dr. Zenithson Ng, clinical associate professor of canine and feline primary care at the University of Tennessee College of Veterinary Medicine. The talk, which was open to the public, provided a unique glimpse into the life of a service dog and revealed ways people can help ensure the welfare of these animals.

A veterinarian who completed a combined American Board of Veterinary Practitioners residency and masters degree program in human-animal bond studies at Virginia Tech, Dr. Ng entitled his presentation, A Day in the Life of a Service Dog: A Welfare Perspective. He began by sharing a documentary clip comprised of interviews with several service dog owners. One person in the video described a time when he wanted to cross a street and urged his dog, Bryson, to move forward. Bryson, however, could sense there was an out of control car headed their way and stayed put to keep his owner out of the road. According to the owner, Bryson disobeyed me to protect me! The full documentary, titled Pick of the Litter, is available to stream on Netflix.

Dr. Ng went on to explain how dogs are chosen for this kind of life of service as soon as they are born. Since service dogs basically work 24 hours per day, seven days per week, careful time and consideration is given to making sure the dogs are up to the duties required in this role.

One particular group of people that can really benefit from service dogs is children with special needs. Dr. Ng gave a hypothetical example of a dog named Grace working as a service dog for a young boy named Mikey who is on the autism spectrum. Mikey has some atypical social tendencies and trouble self-regulating. Grace can be there for him to provide comfort and so he would always have someone trustworthy by his side. This scenario illustrates a fantastic situation in which both Mike and Grace get a beloved friend that loves them unconditionally.

Toward the end of the presentation, Dr. Ng gave another speculative example of a typical day for a service dog attached to a child with autism. There are a number of risks these dogs are subject to, such as obesity, as sometimes the children tend to overfeed them. Also, most often in the school setting, the dogs can experience sensory overload due to being surrounded by many children who want to pet them. Dr. Ng explained that in such situations, what helps most often is communication between the parents and teachers regarding the service dog, to ensure that the dog at school is taken care of like any other pet. Additionally, it is beneficial for teachers to treat the dog as if it were a fellow employee, because the dog is there to support the advancement of the childs education.

Along with dogs, there are many other animals that have been shown to form strong bonds with children who have special needs. A study published in 2013 by the National Center for Biotechnology Information shows children with autism who bonded with guinea pigs experienced a much larger increase in social behaviors compared to children who were given typical toys instead. Additionally, therapeutic horseback riding has been shown to help children cope with stress and relax.

Purdue Veterinary Medicine researchers in the OHAIRE lab, led by Dr. Maggie OHaire, as part of the Purdue University Center for the Human-Animal Bond, also continue to conduct collaborative studies aimed at understanding the effects of animal-assisted intervention for autism.

The Elanco Human-Animal Bond Lecture serves as one of the keynote lectures of the annual Purdue Veterinary Conference. Sponsored by an endowment from Elanco Animal Health, the lecture highlights the special bond between humans and animals.

Writer(s): Jonathan Martz, PVM Communications Intern | pvmnews@purdue.edu

See original here:
Human-Animal Bond Expert Shares How Service Dogs Do the World a Great Service - Purdue Veterinary News

Coinciding with World Rabies Day, Egypts Veterinary Medicine Directorate in the Red Sea signed an agreement on Monday with a local animal shelter to spay and neuter stray dogs in the area. The shelter in Hurghada has thus far fixed 1,547 dogs.

The shelter collects dogs from the streets, anesthetizes them, and sends them to a veterinary clinic affiliated with the shelter in preparation for sterilization.

After the surgery, the dogs are placed under observation for 24 hours before returning to the streets. Antibiotic injections are administered to ensure the surgery wounds heal quickly.

Numerous complaints have been filed by residents of Ras Gharib, a town located in the northernmost area of the Red Sea Governorate.

Residents are worried about the proliferation of stray dogs in the city, citing the threat stray dogs pose to their health and safety. They are calling for a similar sterilization campaign like that of Hurghada.

The Ministry of Agriculture and Land Reclamation reported 400,000 cases of dog bites in Egypt in 2017, up from 300,000 in 2014. 231 people died from animal bites in the past four years, mainly due to rabies.

According to a survey by Egypts Society for the Prevention of Cruelty to Animals, there are more than 15 million stray dogs in Egypt.

Almost every neighborhood in the country is home to stray animals, who can usually be found rummaging through trash for leftover food or loping along city streets.

Edited translation from Al-Masry Al-Youm

See the article here:
Red Sea veterinary authorities spay and neuter 1547 dogs in cooperation with local animal shelter - Egypt Independent

MADISON (WKOW) -- Wisconsin Gov. Tony Evers ordered flags to be flown at half-staff in honor of World War II Veteran Sgt. Duane O. Cole and former State Representative Dr. Jacob (Doc) Hines.

A pair of orders from the governor say the United States flag and the Wisconsin state flag should be flown at half-staff from sunrise to sunset on Saturday, October 3, 2020.

Former State RepresentativeDr. Jacob (Doc) Hines passed away on March 3, 2020, at 92 years old.

Doc Hines was an pillar of his community, practicing veterinary medicine for 53 years, serving in the State Assembly, and contributing to countless organizations, boards, and his church, Evers said in a written statement. He was a dedicated public servant, and on behalf of the state of Wisconsin, I offer my condolences to his family, friends, and loved ones.

Veteran of World War II, Marine Sgt. Duane O. Cole was killed in action on November 20, 1943, during an attempt to secure the island ofBetioin the Tarawa Atoll of the Gilbert Islands.

His remains were found and excavated in 2014, then accounted for on Sept. 3, 2019. Recently Cole's remains have been returned to Wisconsin for burial.

After so many decades of without closure, my condolences and thoughts are with Sgt. Cole's family and community as they welcome him home to his final resting place, Evers said. On behalf of the state of Wisconsin, we are grateful for his service and sacrifice, and honor his memory.

Read more here:
Gov. Tony Evers orders flags to half-staff for war vet and former state representative - WKOW

Prion disease, opioid withdrawal, and how the brain enables limb movement are three areas of biomedical research recently awarded grants from the Canadian Institutes of Health Research (CIHR), totaling $2.6 million in funding.

The CIHR Project Grant program chose projects led by Drs. Sabine Gilch, PhD, Tuan Trang, PhD, and Patrick Whelan, PhD, all researchers in the University of Calgary Faculty of Veterinary Medicine (UCVM).

This is an outstanding achievement for UCVMs internationally renowned researchers and their research and training programs, says Dr. Baljit Singh, dean of UCVM. The proposals from UCVM achieved a 50 per cent success rate compared to the national average of around 17 per cent in this current competition. This further underscores UCVMs reputation as a unique research intensive veterinary medical faculty.

The federally funded grants are given to only the very highest calibre of human health-related scientific inquiry, so this trifecta of awards from a veterinary medicine faculty is a remarkable feat. Its an achievement made possible through close collaborations between UCVM and the Cumming School of Medicine (CSM), where the project leads hold affiliations.

The CIHR Project Grant program is designed to support ideas that have the potential to advance knowledge, research, health care, health systems, and health outcomes. The following projects received funding for the next five years:

Sabine Gilch

The CIHR awarded Sabine Gilch, pictured above, left,funding for her work targeting cholesterol in the brain to counteract prion diseases.

Prion diseases are deadly and cannot be treated to date. They occur when normal brain proteins become infectious and change shape in a way that forms clumps, killing neurons, which eventually leads to progressive brain damage, says Gilch, an associate professor at UCVM and a Tier II Canada Research Chair in Prion Disease Research.

The goal of our research is to understand the cause and consequences of increased cholesterol levels in brain cells that are infected with prions, and to use this knowledge for identifying new therapeutic targets for the treatment of prion diseases.

A well-known form of prion disease is bovine spongiform encephalopathy (also known as mad cow disease), and the most common human form is Creutzfeldt-Jakob disease. Gilch will investigate how high levels of cholesterol in prion-infected neurons affect transport mechanisms in the brain to better understand why brain cells die in the course of the disease.

She will also explore the use of an antiretroviral drug a type of medication that inhibits reproduction of specific types of viruses, including HIV. This particular drug, in addition to its antiretroviral action, reduces cholesterol in neurons, which Gilch sees as a potential treatment for prion disease.

Since we already have promising results with this drug, we are very excited to continue this line of research.

Tuan Trang

Tuan Trang, pictured above, centre, is an associate professor in the departments of Comparative Biology and Experimental Medicine in UCVM, and Physiology and Pharmacology in CSM, whose research aims to unravel the great paradox of pain. Trangs team was awarded funding to study the causes of opioid withdrawal in partnership with the team of Dr. Gerald Zamponi, senior associate dean (research) CSM and Canada Research Chair. Their grant application was the top-ranked submission on the CIHR Pharmacology and Toxicology Committee.

Opioid withdrawal is a significant medical problem and one of the main reasons for opioid reliance. It impacts many people attempting to limit or stop their opioid use, including those provided a prescription for chronic pain, says Trang.

Interventions that reduce withdrawal can break this cycle of opioid use;however, Trang says existing non-opioid drug options are limited and cause severe side effects, while at the same time, not treating the symptoms of withdrawal very effectively. His team will address the need to understand why opioid withdrawal occurs, and how to alleviate it. They recently discovered that immune cells (microglia) residing within the brain and spinal cord play an important role in opioid withdrawal.

Patrick Whelan

Patrick Whelan, pictured above, right,is a professor of neuroscience at UCVM and CSM, and the Frank LeBlanc chair in spinal cord injury research.He will examine the complex brain mechanisms that enable walking.

One of the major things we dont know is how we select the type of movement and under what conditions, says Whelan. My work strives to understand how the brain engages in motivated behaviours such as walking towards food or escaping from danger.

This is important, he says, since it has applications for people and animals with movement disorders. For example, for those suffering from Parkinsons Disease there is an urgent need for new therapeutic targets. Whelans research has identified dopamine areas within the brain that could be used in those with movement disorders to reverse gait abnormalities.

Sabine Gilchis an associate professor, Department of Comparative Biology and Experimental Medicine, UCVM, adjunct associate professor, Department of Biochemistry and Molecular Biology, CSM, and a member of the Hotchkiss Brain Institute (HBI).

Tuan Trang is an associate professor, Department of Comparative Biology and Experimental Medicine, UCVM, and Department of Physiology and Pharmacology, CSM, and a member of Alberta Childrens Hospital Research Institute (ACHRI) and HBI.

Patrick Whelan is professor and head, Department of Comparative Biology and Experimental Medicine, UCVM, professor, departments of Physiology and Pharmacology, and Clinical Neurosciences, CSM, and a member of ACHRI, HBI and the McCaig Institute for Bone and Joint Health.

The University of Calgarys multidisciplinaryEngineering Solutions for Health: Biomedical Engineeringresearch strategy drives solutions to our most pressing health challenges in disease and injury prevention, diagnosis, and treatments. Our biomedical engineering researchers make a significant impact in our communities by extending lives, improving quality of life, promoting independence, and continuously improving the health system.

Go here to read the rest:
Trio of vet med researchers secures $2.6 million in national funding competition - UCalgary News

The University of Wisconsin-Madisons School of Veterinary Medicine has conducted research that provided new insights into creating an alternative and more widely inclusive seasonal influenza vaccine.

Under Marulasiddappa Suresh, a professor of Immunology in the School of Veterinary Medicine, a team was able to find a method of vaccination that would be able to fight multiple strains of influenza. This vaccination would not have to be administered every year, as the current vaccination is.

This new type of vaccine would utilize T-cells, white blood cells that are essential to the immune system, to protect against influenza. Sureshs team found a way to create T-cell immunity for multiple strains of influenza.

Flu viruses mutate frequently and change between geographic regions; This research is on the verge of developing a universal flu vaccine, Suresh said. This new, adaptable, vaccine will be able to fight many different strains of influenza by attacking a specific protein in the virus, one that is present across different strains.

This vaccination strategy is also being tested against tuberculosis, human respiratory syncytial virus and COVID-19.

Vaccination with the T-cells, instead of with a live virus, makes receiving the vaccine much more widely accessible. Live virus vaccinations can be harmful to those who are pregnant and immunocompromised, but having a T-cell based vaccination would remedy this issue.

People who are pregnant or immunocompromised were not given the live virus vaccine due to risk of getting the virus. These demographics would now be able to receive a vaccination without this risk of further compromising their immune systems.

While this research is being conducted, UHS is administering flu vaccinations to students and employees on campus at Nielsen Tennis Stadium and the Nicholas Recreation Center. This vaccination is inactivated -- meaning there is no live virus in the vaccine -- and needs to be taken annually. Flu shots given by UHS are meant to protect you and those around you, the university says appointments can be made online through UHS.

See original here:
UW researches more effective and inclusive flu vaccine - Daily Cardinal

The New Guinea singing dog.

Courtesy of Brian Davis

A recent international study co-authored by a Texas A&M University professor discovered that the New Guinea singing dog, a population thought to be extinct in the wild, shares nearly its entire genetic identity with the New Guinea highland dog, a rarely seen wild population in the islands high-altitude, mountain regions.

According to Brian Davis, a co-senior author of the study and a research assistant professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, this suggests that the two dog populations diverged within the past few decades and are essentially from the same population. Their work is published in PNAS (Proceedings of the National Academy of Science).

About 50 years ago, scientists brought a small number of singing dogs into captivity, and though there are more individuals living in zoos today, they are all descended from the initial founders, and have extremely low genetic diversity.

Because the captive group of singing dogs is severely inbred, this new information could support a conservation program with the potential to save the singing dogs and bring their population back from the brink of extinction.

The research project began in 2018, when James Mac MacIntyre, the head of the New Guinea Highland Wild Dog Foundation, led an expedition into the mountains to collect blood samples from highland dogs.

These samples were sent to Davis, who analyzed the highland dog DNA and compared samples collected from captive singing dogs, named for their unique vocalizations that resemble a wolf howl combined with a whale song.

We assessed about 200,000 genetic markers across the genome, Davis said. Once we sampled these markers, my colleague Heidi Parker at the National Institutes of Health, whos a fantastic canine geneticist, compared these markers with more than 1,500 other dogs.

We basically did an all-to-all comparison to find their place in the tree of life for dogs, he said. When we found out that the highland dogs were most similar to the singing dogs, we knew we had something.

Researchers found that the singing and highland dogs have highly similar genomes.

Courtesy of Brian Davis

He discovered that while all dogs in Oceania (the geographical region including Australia, New Guinea and nearby islands) descend from the same ancestral population, the singing and highland dogs have highly similar genomes. Additionally, the highland dogs do not appear significantly hybridized with any other population of dog, reinforcing their unique place in dog evolution.

In addition to advancing the knowledge of the singing dog population, this project also inspired many questions to fuel future studies.

Now were trying to understand the timing in which each Oceania population branched off, Davis said. Thats going to be the subject of some future work, especially when we get more samples. We also hope to understand where these dogs are along the domestication continuum.

Davis hopes that genetic material from the wild highland dog population can be used to improve genetic health among the captive singing dogs and rebuild their population.

Having a higher genetic diversity is essential to long-term survival, Davis said. The singing dogs in captivity are derived from only a small number of individuals and theyre very inbred. These highland wild dogs are the only dogs like them. The singing dogs may look similar to dogs like the dingo, but they have novel vocalizations and behaviors that no other dog has. Even the way that they walk is different.

While the effort to rebuild the singing dog population will take many years, Davis believes it is a worthwhile cause to preserve the unique species.

As an evolutionary biologist, I want to conserve everything that exists, Davis said. Its important that these animals be conserved and that we study them and understand their population. We need to appreciate the adaptations that theyve undergone that no other dog has, and potentially help protect them as the environment changes and they have to change with it.

Read the rest here:
Discovery Provides Hope For Singing Dogs On Brink Of Extinction - Texas A&M University Today

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRFs initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.

SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.

Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART. In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society, says Krystyn Van Vliet, co-lead principal investigator at SMART CAMP, professor of materials science and engineering, and associate provost at MIT.

Understanding glaucoma progression for better-targeted treatments

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, MIT, and National University of Singapore (NUS). The team will seek to establish first principles-founded and statistically confident models of glaucoma progression in patients. Through retinal biomechanics, the models will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better-targeted treatments.

Glaucoma, an eye condition often caused by stress-induced damage over time at the optic nerve head, accounts for 5.1 million of the estimated 38 million blind in the world and 40 percent of blindness in Singapore. Currently, health practitioners face challenges forecasting glaucoma progression and its treatment strategies due to the lack of research and technology that accurately establish the relationship between its properties, such as the elasticity of the retina and optic nerve heads, blood flow, intraocular pressure and, ultimately, damage to the optic nerve head.

The research is co-led by George Barbastathis, principal investigator at SMART CAMP and professor of mechanical engineering at MIT, and Aung Tin, executive director at SERI and professor at the Department of Ophthalmology at NUS. The team includes CAMP principal investigators Nicholas Fang, also a professor of mechanical engineering at MIT; Lisa Tucker-Kellogg, assistant professor with the Cancer and Stem Biology program at Duke-NUS; and Hanry Yu, professor of physiology with the Yong Loo Lin School of Medicine, NUS and CAMPs co-lead principal investigator.

We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction, says Barbastathis.

Cell transplantation to treat irreparable spinal cord injury

Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), the second research project, gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), the University of Cambridge, and MIT. The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project, an intersection of engineering and health, will achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimized engineering methods to prepare cells and biomaterials for treatment.

Spinal cord injury (SCI), affecting between 250,00 and 500,000 people yearly, is expected to incur higher societal costs as compared to other common conditions such as dementia, multiple sclerosis, and cerebral palsy. SCI can lead to temporary or permanent changes in spinal cord function, including numbness or paralysis. Currently, even with the best possible treatment, the injury generally results in some incurable impairment.

The research is co-led by Chew Sing Yian, principal investigator at SMART CAMP and associate professor of the School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at NTU, and Laurent David, professor at University of Lyon (France) and leader of the Polymers for Life Sciences group at CNRS Polymer Engineering Laboratory. The team includes CAMP principal investigators Ai Ye from Singapore University of Technology and Design; Jongyoon Han and Zhao Xuanhe, both professors at MIT; as well as Shi-Yan Ng and Jonathan Loh from Institute of Molecular and Cell Biology, A*STAR.

Chew says, Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many. Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the health-care industry and society, says Hanry Yu, co-lead principal investigator at SMART CAMP, professor of physiology with the Yong Loo Lin School of Medicine, NUS, and group leader of the Institute of Bioengineering and Nanotechnology at A*STAR.

The grants for both projects will commence on Oct. 1, with RAMP expected to run until Sept. 30, 2022, and ScaNCellS expected to run until Sept. 30, 2023.

SMART was. established by the MIT in partnership with the NRF in 2007. SMART is the first entity in the CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five interdisciplinary research groups (IRGs): Antimicrobial Resistance, CAMP, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

CAMP is a SMART IRG launched in June 2019. It focuses on better ways to produce living cells as medicine, or cellular therapies, to provide more patients access to promising and approved therapies. The investigators at CAMP address two key bottlenecks facing the production of a range of potential cell therapies: critical quality attributes (CQA) and process analytic technologies (PAT). Leveraging deep collaborations within Singapore and MIT in the United States, CAMP invents and demonstrates CQA/PAT capabilities from stem to immune cells. Its work addresses ailments ranging from cancer to tissue degeneration, targeting adherent and suspended cells, with and without genetic engineering.

CAMP is the R&D core of a comprehensive national effort on cell therapy manufacturing in Singapore.

See the original post:
SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy - MIT News

When people find out Azizi Seixas studies sleep, they sometimes ask him about their dreams. Thats not really his fieldbut he does have big dreams for his own research. By using technology to combine precision medicine with population-level research, he hopes to erase disparities and bring better health to all.

Growing up in inner-city Kingston, Jamaica, I was the have-nots, Seixas says. He learned early lessons about inequality andbeing raised by seven women in a three-bedroom homeresourcefulness. Today hes carried those lessons to New York Universitys Grossman School of Medicine, where hes an assistant professor of population health and psychiatry. In his lab, Seixas explores why certain groups such as racial and ethnic minorities have higher risks of chronic illnesses, the long-term consequences of those disparities, and how people can change their behavior to improve their health.

Sleep has been a kind of lens through which Seixas looks at these questions. For example, how are disparities in peoples sleep related to heart disease risk and other health effects? And how might doctors tailor sleep advice to individuals, along with their other recommendations?

Thats important because sleep plays an integral role in our health 24/7, not just the hours were in bed. Sleep is not just the act of unconsciousness, Seixas says. Besides keeping our bodies refreshed and running, sleep is important for consolidating things weve learned, and for cleansing our brains of protein gunk thats linked to Alzheimers disease.

Yet not everyone can get as much sleep as they need. He gives the example of a single mother who works two jobs. If he tells her she needs to sleep eight or nine hours a night, Shell look at me and scoff, Seixas says. And they have, to be quite honest.

Seixas imagines working with that single mom to figure out ways to offset her lost sleep using other health recommendations. Maybe dialing up her exercise can lower her risk of certain diseases, even while she continues squeezing in just six hours a night. If exercising more isnt feasible, maybe she can adjust her diet instead. The data to make this happen might come from wearable technologies that track the moms activities and biometrics, as well as artificial intelligence and machine-learning models that predict how changes to her behaviors will affect her health.

Scientists are still learning about the intricate ways our traits, behaviors, and risks may affect each other, so this scenario is still hypothetical. But one goal of Seixass research is to be able to personalize the advice a doctor gives a patient, rather than assuming that the same guidance is right for everybody. Seixas calls his philosophy precision and personalized population health. He thinks general guidelines for the public are important, too. But to fulfill what he calls his sacrosanct role in public health, he wants to find precisely the right way to help that single mother, or anyone else, stay healthy.

How is their nightly sleep related to their daily steps?

Some of his research hints that it might be possible. In a 2018 paper, he and his colleagues used machine learning to analyze survey data from more than 280,000 people about whether theyd had a stroke, as well as their age, sex, nightly sleep, and physical activity. The analysis showed which combinations of factors put people at higher or lower risk of strokes. In a similar 2017 paper, Seixas and others calculated which combinations of activity, sleep, stress, and body mass index were linked to the lowest diabetes risk in Black and white Americans.

The more health data he can include from a diverse range of people, the better the recommendations that might emerge from it. Among many other projects to help improve these datasets, Seixas is soon launching a study with funding from Merck that will focus on people with hypertension and diabetes. Seixas and his team created an app that will give participants higher-level analyses from the Fitbits or other health trackers they already use. For example, how is their nightly sleep related to their daily steps? The app will also automatically gather health-related news and articles that might interest the user. And, critically, it will tell users about clinical trials they can enroll in. We want to appeal to the greater good of individuals, Seixas says, tapping into peoples drive for altruism and volunteering to fight chronic health conditions.

Encouraging more people to enroll in clinical trialswhich include trials of behavioral changes, not just tests of new drugscould help researchers get better data on underrepresented groups. Seixas hopes it could also help the public to see science in a positive light. Especially now, he says, where you have political figures questioning whether or not science should be the bright force that it has always been.

Seixass ideas are especially timely during COVID-19, says Girardin Jean-Louis, a professor of population health and psychiatry at NYU Langone Health, who is Seixass mentor. During the pandemic, vulnerable communities are having an especially hard time accessing healthcare. His research is poised to address how various health issues plaguing underserved communities can be addressed adequately, Jean-Louis says.

Seixas hopes the questions he and his research group at NYU are asking will someday help to transform healthcare. We have very ambitious dreams and goals, he says.

Go here to read the rest:
Big Dreams of Personalized Health - NEO.LIFE

The global Personalized Medicine market focuses on encompassing major statistical evidence for the Personalized Medicine industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Personalized Medicine study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Personalized Medicine industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Personalized Medicine market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Personalized Medicine report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Personalized Medicine market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Personalized Medicine Market report @ https://hongchunresearch.com/request-a-sample/41081

Key players in the global Personalized Medicine market covered in Chapter 4:Amgen Inc.GE HealthcareSiemens Healthcare Diagnostics Inc.Asuragen IncQiagen Inc.Becton Dickinson & Co.Agendia NVPfizer Inc.Bristol-Myers SquibbAbbott

In Chapter 11 and 13.3, on the basis of types, the Personalized Medicine market from 2015 to 2026 is primarily split into:PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

In Chapter 12 and 13.4, on the basis of applications, the Personalized Medicine market from 2015 to 2026 covers:Diagnosis and interventionDrug development and usageCancer genomics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Personalized Medicine market study further highlights the segmentation of the Personalized Medicine industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Personalized Medicine report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Personalized Medicine market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Personalized Medicine market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Personalized Medicine industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Personalized Medicine Market Report with [emailprotected]https://hongchunresearch.com/report/personalized-medicine-market-41081

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Personalized Medicine Market

Chapter Four: Players Profiles

Chapter Five: Global Personalized Medicine Market Analysis by Regions

Chapter Six: North America Personalized Medicine Market Analysis by Countries

Chapter Seven: Europe Personalized Medicine Market Analysis by Countries

Chapter Eight: Asia-Pacific Personalized Medicine Market Analysis by Countries

Chapter Nine: Middle East and Africa Personalized Medicine Market Analysis by Countries

Chapter Ten: South America Personalized Medicine Market Analysis by Countries

Chapter Eleven: Global Personalized Medicine Market Segment by Types

Chapter Twelve: Global Personalized Medicine Market Segment by Applications12.1 Global Personalized Medicine Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Personalized Medicine Sales and Market Share by Applications (2015-2020)12.1.2 Global Personalized Medicine Revenue and Market Share by Applications (2015-2020)12.2 Diagnosis and intervention Sales, Revenue and Growth Rate (2015-2020)12.3 Drug development and usage Sales, Revenue and Growth Rate (2015-2020)12.4 Cancer genomics Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Personalized Medicine Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/41081

List of tablesList of Tables and FiguresTable Global Personalized Medicine Market Size Growth Rate by Type (2020-2026)Figure Global Personalized Medicine Market Share by Type in 2019 & 2026Figure PM Diagnostics FeaturesFigure PM Therapeutics FeaturesFigure Personalized Medical Care FeaturesFigure Personalized Nutrition & Wellness FeaturesTable Global Personalized Medicine Market Size Growth by Application (2020-2026)Figure Global Personalized Medicine Market Share by Application in 2019 & 2026Figure Diagnosis and intervention DescriptionFigure Drug development and usage DescriptionFigure Cancer genomics DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Personalized Medicine Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Personalized Medicine Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Personalized MedicineFigure Production Process of Personalized MedicineFigure Manufacturing Cost Structure of Personalized MedicineFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table GE Healthcare ProfileTable GE Healthcare Production, Value, Price, Gross Margin 2015-2020Table Siemens Healthcare Diagnostics Inc. ProfileTable Siemens Healthcare Diagnostics Inc. Production, Value, Price, Gross Margin 2015-2020Table Asuragen Inc ProfileTable Asuragen Inc Production, Value, Price, Gross Margin 2015-2020Table Qiagen Inc. ProfileTable Qiagen Inc. Production, Value, Price, Gross Margin 2015-2020Table Becton Dickinson & Co. ProfileTable Becton Dickinson & Co. Production, Value, Price, Gross Margin 2015-2020Table Agendia NV ProfileTable Agendia NV Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Bristol-Myers Squibb ProfileTable Bristol-Myers Squibb Production, Value, Price, Gross Margin 2015-2020Table Abbott ProfileTable Abbott Production, Value, Price, Gross Margin 2015-2020Figure Global Personalized Medicine Sales and Growth Rate (2015-2020)Figure Global Personalized Medicine Revenue ($) and Growth (2015-2020)Table Global Personalized Medicine Sales by Regions (2015-2020)Table Global Personalized Medicine Sales Market Share by Regions (2015-2020)Table Global Personalized Medicine Revenue ($) by Regions (2015-2020)Table Global Personalized Medicine Revenue Market Share by Regions (2015-2020)Table Global Personalized Medicine Revenue Market Share by Regions in 2015Table Global Personalized Medicine Revenue Market Share by Regions in 2019Figure North America Personalized Medicine Sales and Growth Rate (2015-2020)Figure Europe Personalized Medicine Sales and Growth Rate (2015-2020)Figure Asia-Pacific Personalized Medicine Sales and Growth Rate (2015-2020)Figure Middle East and Africa Personalized Medicine Sales and Growth Rate (2015-2020)Figure South America Personalized Medicine Sales and Growth Rate (2015-2020)Figure North America Personalized Medicine Revenue ($) and Growth (2015-2020)Table North America Personalized Medicine Sales by Countries (2015-2020)Table North America Personalized Medicine Sales Market Share by Countries (2015-2020)Figure North America Personalized Medicine Sales Market Share by Countries in 2015Figure North America Personalized Medicine Sales Market Share by Countries in 2019Table North America Personalized Medicine Revenue ($) by Countries (2015-2020)Table North America Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure North America Personalized Medicine Revenue Market Share by Countries in 2015Figure North America Personalized Medicine Revenue Market Share by Countries in 2019Figure United States Personalized Medicine Sales and Growth Rate (2015-2020)Figure Canada Personalized Medicine Sales and Growth Rate (2015-2020)Figure Mexico Personalized Medicine Sales and Growth (2015-2020)Figure Europe Personalized Medicine Revenue ($) Growth (2015-2020)Table Europe Personalized Medicine Sales by Countries (2015-2020)Table Europe Personalized Medicine Sales Market Share by Countries (2015-2020)Figure Europe Personalized Medicine Sales Market Share by Countries in 2015Figure Europe Personalized Medicine Sales Market Share by Countries in 2019Table Europe Personalized Medicine Revenue ($) by Countries (2015-2020)Table Europe Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure Europe Personalized Medicine Revenue Market Share by Countries in 2015Figure Europe Personalized Medicine Revenue Market Share by Countries in 2019Figure Germany Personalized Medicine Sales and Growth Rate (2015-2020)Figure UK Personalized Medicine Sales and Growth Rate (2015-2020)Figure France Personalized Medicine Sales and Growth Rate (2015-2020)Figure Italy Personalized Medicine Sales and Growth Rate (2015-2020)Figure Spain Personalized Medicine Sales and Growth Rate (2015-2020)Figure Russia Personalized Medicine Sales and Growth Rate (2015-2020)Figure Asia-Pacific Personalized Medicine Revenue ($) and Growth (2015-2020)Table Asia-Pacific Personalized Medicine Sales by Countries (2015-2020)Table Asia-Pacific Personalized Medicine Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Personalized Medicine Sales Market Share by Countries in 2015Figure Asia-Pacific Personalized Medicine Sales Market Share by Countries in 2019Table Asia-Pacific Personalized Medicine Revenue ($) by Countries (2015-2020)Table Asia-Pacific Personalized Medicine Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Personalized Medicine Revenue Market Share by Countries in 2015Figure Asia-Pacific Personalized Medicine Revenue Market Share by Countries in 2019Figure China Personalized Medicine Sales and Growth Rate (2015-2020)Figure Japan Personalized Medicine Sales and Growth Rate (2015-2020)Figure South Korea Personalized Medicine Sales and Growth Rate (2015-2020)Figure Australia Personalized Medicine Sales and Growth Rate (2015-2020)Figure India Personalized Medicine Sales and Growth Rate (2015-2020)Figure Southeast Asia Personalized Medicine Sales and Growth Rate (2015-2020)Figure Middle East and Africa Personalized Medicine Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Trending Report URLs:

COVID-19 Outbreak- Global Water Filter Dispensers Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2026

Global Urology Disposable Market Size, Share, 2020 Movements by Key Findings, Covid-19 Impact Analysis, Progression Status, Revenue Expectation to 2026

Read more:
Covid-19 Impact on Personalized Medicine Market Globally Growth Analysis 2020-2026 | Business Opportunities by Evolving Technologies, Global Size...

SAN ANTONIO, Oct. 1, 2020 /PRNewswire/ --Innovative Gx Laboratories, a Texas-based molecular diagnostic company, is announcing the grand opening of its central testing laboratory in San Antonio, Texas, on Oct. 1, 2020. Innovative Gx specializes in molecular diagnosis using real-time RT PCR and DNA sequencing in many medical areas. The company is a leader in personalized medical solutions such as Respiratory Pathogens, Infectious Disease, COVID-19, and DNA-based Pharmacogenetics (PGX) testing services delivering genetic-based treatment of patient care.

Innovative Gx Laboratories was founded in 2019by a team of careermedical diagnostic scientists with a combined 30+ years of experience. Its scientific team is dedicated to providing the highest-quality clinical testing services to help people reach the best health through personalized medicine. The company offers high-accuracy testing, ship-to-home (reviewed by an independent physician) or B2B solutions, offering diagnostic kitsand rapid results (often delivered in as little as less than 24 hours) for its physicians, hospitals, and clinics it serves nationwide.

Innovative Gx Laboratories provides one of the most comprehensive molecular testing options for physicians to help them accurately diagnose and treat many diseases through its targeted pharmacogenomic (PGX) panels. At present, Innovative Gx PGX panels include medications commonly prescribed to treat cardiovascular disease, mental health, infectious disease, cancer, and adverse drug interactions, and examineover 62 genes and 200 gene variants.

Innovative GX Laboratories also specializes in molecular testing of infectious disease, identification of a large range of respiratory pathogens, and RT PCR-based COVID testing. The Innovative Gx RT PCR COVID-19 Test is considered the "gold standard" in COVID screening and has received FDA authorization for emergency use. The test's level of accuracy is much higher than antigen and antibody testing and attains 99% determination of virus present.

"Our team of scientists and physicians at Innovative Gx Laboratories work diligently to offer the most comprehensive testing panels for our hospitals, physicians, and patients," said Enrique Perez-Paris, one of the co-founders of the company. He added, "Innovative Gx is much more than a business venture. It is my legacy, allowing the team at IG, to help others by providing precise health information in an accurate and timely manner."

For more information about Innovative Gx Laboratories and details of its services, please visit or contact the company at:

Innovative Gx Laboratories5410 Fredericksburg Road, Suite A304, San Antonio, Texas 78229(866) 3PCR-DNA[emailprotected] https://innovativegx.com

Related Files

InnovativeGx Laboratories Grand Opening Press Release.docx

Related Images

logo.jpg Logo

SOURCE Innovative Gx Laboratories

Innovative GX

Read more from the original source:
Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas - PRNewswire

The Nobel Prizes for Physics, Chemistry and Medicine are the acme of scientific achievement -- honoring great minds and life-changing discoveries. But predicting who will be summoned to Stockholm and win the accolades, which are announced next week, is easy to get wrong.

That doesn't mean that people don't try.

Some look at which scientists have won so-called predictor prizes like the Lasker Awards for medical science, others analyze the fields of study favored by the Nobel Committee and tally how many years pass before a specific field is honored.

Complicating matters is that the Nobel selection committee, according to the rules laid down by Swedish industrialist Alfred Nobel in 1895, can only honor up to three people -- something that is getting harder given the collaborative nature of much scientific research.

Pandemic medicine

Unlike the peace prize, which often raises some eyebrows, the science prizes tend to honor achievements that have withstood the test of time -- last year's prize in chemistry recognized research in the development of lithium batteries from the 1980s that included honoring the oldest winner ever. The distinctions in science are thus less likely to generate controversy.

This means that it's highly unlikely that the fast-moving scientific research into Covid-19 will be featured, although many think that a drug to treat the disease or vaccine to stop its spread is a potential future winner.

That said, Gilbert Thompson, professor emeritus of clinical lipidology at Imperial College London, thinks that the committee could honor two scientists, Max Cooper and Jacques Miller, whose discovery about the organization and function of the human immune system, in particular B cells and T cells, is underpinning vaccine research.

Eman Ghanem, membership director at Sigma Xi, a global association of around 30,000 scientists that includes some 200 Nobel prize winners, is hopeful that there will be a female Nobel Laureate in science after an all-male lineup in 2019.

Success! An email has been sent to with a link to confirm list signup.

Error! There was an error processing your request.

Citations

David Pendlebury, a senior citation analyst at Clarivate Analytics, since 2002 has made 54 correct predictions (though not usually in the right year) by analyzing how often a scientist's key papers are cited by peers. Out of some 50 million scientific papers indexed since 1970, only 5,700 (or 0.01%) have been cited 2,000 or more times, and this is the pool from which his prediction are drawn.

"We're not saying that these particular people are going to win in a particular year," Pendlebury said. "We're saying these people are Nobel class and are likely to win a Nobel prize at some point.

For the physics prize, one of three contending groups Pendlebury lists is Carlos Frenk of Durham University, Julio Navarro of University of Victoria in Canada and Simon White, former director at the Max Planck Institute for Astrophysics, for their work into galaxy formation, cosmic structure and dark matter. However, Pendlebury said a win this year is unlikely because last year's physics prize for the first discovery of planets outside our solar system, led by Princeton astrophysicist James Peebles, was from the same field.

"It's highly cited, essential work, but I think it will probably be a few years till they return to a prize in cosmology," he said. "Though they could prove me wrong."

Conservative choices

The CRISPR gene-editing technology, is often mentioned as a candidate for the chemistry prize, but Pendlebury said it was a potential minefield for a Nobel Committee that likes to play it safe.

While worthy, he said several groups of scientists have been collaborating on gene editing, making it hard to narrow it down to three names. Moreover, the technology had until recently been tied up in patent wrangles. (And that's notwithstanding the ethical concerns that have dogged the technology in the wake of Chinese scientist He Jiankui, who was jailed for creating the world's first gene-edited babies.)

"I think they are making conservative choices on the significance of the science," he said.

For medicine, Pendlebury's picks include Yusuke Nakamura, a Japanese geneticist, whose contributions in pioneering whole genome sequencing gave birth to the field of personalized medicine that has revolutionized cancer treatment; and Lebanese scientist Huda Y. Zoghbi, for her work on neurological disorders including the genetic origins of Rett syndrome, a rare genetic neurological disorder that occurs primarily in girls. She was the 2017 winner of a $3 million Breakthrough Prize in Life Sciences -- founded by Sergey Brin, Priscilla Chan and Mark Zuckerberg.

"She's a very good example of someone who's likely to get Nobel recognition because of the awards she's been getting," Pendlebury said. "It's not just the accumulation of citations. Receiving these top prizes, which are chosen and selected by your peers, you get a stronger and stronger signal of how important this work has been."

Read the original here:
Why it's so hard to guess who's going to get a Nobel Prize - The Albany Herald

Hamad Bin Khalifa University (HBKU), a member of Qatar Foundation for Education, Science, and Community Development (QF), was founded in 2010 to continue fulfilling QFs vision of unlocking human potential. HBKU is a homegrown research and graduate studies University that acts as a catalyst for positive transformation in Qatar and the region while having a global impact.

About Qatar Biomedical Research Institute:

Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University (HBKU), is a national center of excellence in biomedical research. It aims to transform healthcare through harnessing and converting the latest advances in science, medicine and technology into novel discoveries that will lead to more effective treatments and preventive strategies for human diseases such as: diabetes, cancer and neurological disorders. The institute strives toward the development of novel diagnostic and therapeutic strategies to facilitate early diagnosis, treatment and management of these devastating diseases with the purpose of improving personalized medicine and healthcare. QBRI has recently occupied state-of-the-art life sciences laboratories in a newly established research campus.

Job Purpose:

To lead and develop a team of scientists and researchers leading to QBRI's growth and address developmental healthcare needs of Qatar. Conceive and establish competitive research programs including conducting translational research.

Key Result Areas:

Operating Environment, Framework & Boundaries:

Communications and Working Relationships:

Problem Solving & Complexity:

Decision-Making Authority & Responsibility:

Minimum Knowledge, Skills & Experience:

Additional Requirements

How to apply

Please submit your completed application (CV, cover letter and the names of three references with their full contact information) via the following link: Click here to apply

Hamad Bin Khalifa University, being an equal opportunity educator and employer, is committed to maintaining culturally and academically diverse staff of the highest caliber.

Read more:
Principal Investigator job with HAMAD BIN KHALIFA UNIVERSITY | 227841 - Times Higher Education (THE)

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country" - https://www.reportlinker.com/p05974341/?utm_source=GNW Additionally, the 3D printing technology offers a huge opportunity for medical companies in empowering a rapid production of medical implants, as well as transforming the way of planning procedures by surgeons and doctors.

Moreover, 3D-printed anatomical models are becoming essential and useful tools in the current practice of precision medicine as well as for personalized treatments.Also, additive manufacturing for the healthcare industry is still an ongoing process; however, it has already been applied in several different techniques in the medical field.

These developments in the medical field have increased the applications of stepper motors, thus, supporting the growth of stepper motor market.Based on type, the stepper motor market is further segmented into integrated lead screw stepper motor, rotary stepper motor, and fully-enclosed stepper drives.The rotary stepper motor segment held the largest share of the stepper motor market in 2019.

Rotary stepper motors are brushless and synchronous electric motors, which split a full rotation of the motor into number of equal steps.They act as synchronous AC motors comprising several poles, which are mounted on both rotor and stator.

These motors are used in a wide range of systems in an industrial setup, such as multi-axis machines, CNC machines, rotation stages, high-speed pick and place equipment, constantly driving linear actuators, linear stages, lead screws or ball screws, and mirror mounts.Several governments in APAC are taking possible steps to reduce the effects of COVID19 by announcing lockdown, which is impacting the revenue generated by the market.Although, China is one of the leading manufacturing sectors in the region, it is the most affected country in APAC due to COVID-19.

However, China has been able to minimize the spread of COVID-19, and the industries are back to normal run.Several players in the country have witnessed decline in market trends over the past three months.

Further, India, Japan, South Korea, and Taiwan are still combating the virus, and are exercising lockdown, which is hampering the growth of stepper motor market.The overall APAC stepper motor market size has been derived using primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the stepper motor market.

The process also serves the purpose of obtaining an overview and forecast for the APAC stepper motor market with respect to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.

The participants who take part in such a process include industry experts such as VPs, business development managers, stepper motor market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the APAC stepper motor market. FAULHABER Group; Oriental Motor USA Corp.; SANYO DENKI CO., LTD; Nidec Corporation; Nippon Pulse Motor Co. Ltd.; ABB Ltd.; Schneider Electric SE; National Instruments Corporation; and Delta Electronic are among a few players operating in the APAC stepper motor market.Read the full report: https://www.reportlinker.com/p05974341/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:
Asia Pacific Stepper Motor Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Technology, and End user, and Country -...

TipRanks

President Trumps announcement that he has tested positive for the corona virus has grabbed headlines, but the dog that didnt bark presents a more interesting point. Wall Street isnt so worried about corona virus anymore; the perception is, that the virus will fade away or a vaccine will be developed, but in either case, the economy will improve.According to an RBC survey of portfolio managers, however, the coming November election presents a clear risk to the markets. A large majority of investors surveyed, 76%, worry that the election will be contested, resulting in weeks possibly months on uncertainty. And uncertainty is bad for the markets.Recent events, and some not-to-distant history, bear them out. For the history, we must only look back to 2000, when it took until December 12, and an appeal to the Supreme Court, to decide the results of the Florida recount. The S&P 500 slipped 5% during those weeks and that was uncertainty caused by one state, recounting a limited number of votes. The point here is not that this election will be fraudulent or illegitimate. Rather, like Caesars wife, the election should be above the perception of impropriety and this year, that bar may be too high. And then the challenges will begin. In the RBC survey, 83% of portfolio managers believed that such challenges, contesting the election results (from either direction) would be a net negative for the stock market. And only a small minority, 14%, believe that the final results will be known when the polls close on Election Day, November 3.And this is what brings us to dividend stocks today. When investors get nervous, they go looking for a way to protect their portfolios and dividends, making the promise of a steady income stream, may be just the answer skittish shareholders are looking for.Analysts from research firm Compass Point agree. They have picked three stocks whose dividends are yielding 7% or more. Weve pulled up the TipRanks data to find out what else makes these compelling buys in turbulent times.Saratoga Investment Corporation (SAR)Well start with Saratoga Investment Corporation, a mid-market investment management company that specializes in debt, appreciation, and equity investments. Saratoga has over $480 million in assets under management, and its portfolio includes home security, industry, software, and waste disposal. The variety, and the stocks chosen, are designed to give the company a resilient income stream.That doesnt mean that Saratoga has been able to dodge the corona bullet. The company saw revenues turn negative in Q2, and has seen EPS slip from 61 cents in the first quarter to 51 cents in the second. As a result, Saratoga announced that it was deferring its fiscal Q4 dividend, as a cash-saving measure during the pandemic crisis.Saratoga, in July, declared its fiscal Q1 dividend for 40 cents per common share and paid it out in August. There are grounds for confidence. The company has $9 million in committed, but undrawn, lending available, along with $155 million in available credit facilities, a new $43.1 million baby bond issue, and $282 million equity all set against just $60 million in long-term debt.As for the restored dividend, while down 28% from the companys last dividend payment, the new distribution reflects Saratogas liquidity position. The current payment annualizes to $1.60, and gives a yield of 9.2%, or more than 4.5x the average yield found among S&P-listed companies.Covering the stock for Compass Point, analyst Casey Alexander writes of the new dividend, [With] the dividend now officially reset at $0.40 per quarter, it's time to make lemonade from the lemons investors were handed In our view, while we may not be done with credit issues, SAR has set the dividend at a level that allows the BDC to return to the pattern of QoQ dividend increases as the current earnings power of the BDC well exceeds the level of the new dividend.Taking everything into account, Alexander rates SAR stock a Buy, and gives it a $19.75 price target implying an upside of 16% for the coming year. (To watch Alexanders track record, click here)Overall, Saratoga gets a unanimous Strong Buy rating from the analyst consensus, based on 3 recent positive reviews. The shares are selling for $17.02 and have an average price target of $22.58, slightly more bullish than Alexanders and suggesting a one-year upside of ~33%. (See SAR stock analysis on TipRanks)Solar Capital, Ltd. (SLRC)The next stock on our list, Solar Capital, is an investor in senior secured loans and subordinated debt, with an investment portfolio of middle-market companies. The company puts capital into investment-grade loan instruments, making additional financing available to its customer base. Solar Capital has a portfolio worth $1.4 billion invested in 183 companies across 80 business sectors.Solar Capital has been able to keep earnings positive during the corona half, despite a sharp fall in the bottom line for Q1 and Q2. In a bright spot, revenues, which turned negative in Q1, were back to positive in Q2, and projections for Q3 earnings show that the fall-off is either slowing or stopping we will find out which in the Q3 report on November 5.Through all of this uncertainty, Solar Capital has kept up its stable dividend. The company has a 7-year history of reliable dividend payments, and the current quarterly dividend of 41 cents has been paid out consistently for the last 11 quarters. At an annualized payment of $1.64, the dividend currently yields 10.5%. In a time of near-zero official interest rate policy, this gives SLRC an enviable return.Compass Point's Casey Alexander, who also covers SAR, points out that SLRCs dividend is the main attraction for investors and that management has cultivated it for just that purpose. Management stated their intention to continue to pay the $0.41 per share dividend because they believe there is visibility to dividend coverage as they begin to originate new assets at higher spreads. This is the environment that SLRC has been waiting for, and has been the principal reason for maintaining an under-leveraged posture for the last several years, Alexander noted.With dividend coverage visible ahead, Alexander gives SLRC a Buy rating. His price target, at $17.75, indicates confidence in a 12% upside potential.This is another stock with a unanimous Strong Buy consensus rating. SLRC is sitting pretty with 5 positive reviews on record. The average price target is $18.20, representing a ~15% upside from the current share price of $15.86. (See SLRC stock analysis on TipRanks)First Hawaiian (FHB)Our last stock today, First Hawaiian, is the holding company owning the First Hawaiian Bank. First Hawaiian offers the usual array of banking services to retail and commercial customers, with 53 branches throughout the Hawaiian Islands along with three others in Guam and two on Saipan. Banking services include loans, deposit accounts, credit and debit cards, mortgages, insurance, and retirement plans.The recently ended second-quarter showed some mixed results. Top line revenues showed a sequential slip, from $164 million to $152 million, but that was mild compared to the 46% drop in earnings. EPS for Q2 came in at 16 cents, on $20 million in net income. Bright spots for the quarter were total loans, which grew 3% to $383 million, and deposit balances, which increased 13% sequentially to reach $2.3 billion. The banks total assets at the end of 2Q20 were $23 billion, up 10% from the end of the first quarter.That is the background behind managements July dividend declaration. The company Board approved a 26-cent regular quarterly dividend, which was paid out in early September. At $1.04 annualized, this dividend yields 7.2%, putting it well above the average yield and far higher than the current yield on Treasury bonds. FHB has a 4-year history of reliable dividend payments, and the current declaration marks the seventh quarter in a row at the current level.Compass Point analyst Laurie Havener Hunsicker believes a macro look at FHB justifies a bullish stance. FHB was a clear outperformer on credit during the last crisis. While past results do not dictate future performance, we are impressed with the FHB management team and their credit culture; further, we believe that FHB is well-postured to again outperform on credit during the COVID-19 crisis, the analyst noted.In line with her comments, Hunsicker rates FHB a Buy and sets a $21 price target that suggests room for a robust share appreciation of 46% over the next year. (To watch Hunsickers track record, click here)However, Wall Street is unsure on FHB, and the analysts are evenly divided, with recent reviews coming in at 1 Buy, 1 Hold, and 1 Sell for an analyst consensus rating of Hold. FHB shares are selling for $14.42 and have an average price target of $16.67, making the upside potential 15%. (See First Hawaiians stock analysis at TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more from the original source:
Whole Exome Sequencing - Global Market Trajectory & Analytics to 2027 with Short-Term COVID-19 Impact Analysis 2020-2021 - ResearchAndMarkets.com...

NEW YORK, Sept. 30, 2020 /PRNewswire/ --The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019. The market is estimated to grow with a CAGR of 13.4% from 2020-2027.

Read the full report: https://www.reportlinker.com/p05974400/?utm_source=PRN

Factors such as growing prevalence of neurological disorders and increasing focus toward research in neurological biomarker are expected to fuel the growth of the market.However, the limitation of neurological biomarkers is a major factor hindering the market growth.

In addition, increasing awareness toward benefits of early diagnosis is expected to provide growth opportunities to the market players for developing new biomarkers whereas, the inclination toward personalized/precision medicine is expected to be a prevalent trend in the market.Biomarkers are the molecules that indicate about the presence of a disease.The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology have enabled to track the health condition of the brain by measuring the biomarkers.

This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.The National Institute of Neurological Disorders and Stroke (NINDS) biomarker program is focused on enhancing the quality and efficiency of neurotherapeutic clinical research and supports the biomarker validation.The program promotes rigorous biomarker identification and validation by providing funds for the research activities.

Similarly, Parkinson's disease Biomarkers Program (PDBP) was initiated to support new and existing research promoting the discovery of biomarker for Parkinson's disease. Thus, increasing number of research studies conducted in the North American region focusing toward advancements in neurological biomarker are expected to augment the growth of the market over the forecast period.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak.This has eventually shifted their focus from development of new neurological biomarkers to vaccine development for COVID-19.

Moreover, diversion of resources from neurological biomarkers development to coronavirus treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, supplies for biotechnology procedures and procurement are also badly affected by the outbreak of COVID-19 in North America.In 2019, the genomic biomarkers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period.This segment is likely to witness a lucrative growth owing to increasing awareness among consumers regarding benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers.

In addition, the trend shift towards adoption of gene counseling and genetic analysis for diagnostic purposes is also likely to augment the growth of the segment. The genetic biomarkers are significant modalities that directs towards a more personalized approach of predispositions and medical analysis.Some of the significant secondary sources for neurological biomarkers market included in the report are the World Health Organization (WHO), Food and Drug Administration (FDA),National Institute of Neurological Disorders and Stroke (NINDS),Centers for Disease Control and Prevention (CDC),and others.

Read the full report: https://www.reportlinker.com/p05974400/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

View original post here:
The North America neurological biomarkers market is expected to reach US$ 2,618.68 Mn in 2027 from US$ 7,056.76 Mn in 2019 - PRNewswire

Some of the prominent players operating in the precision medicine software market include 2bPrecise, Syapse, Inc., IBM Corporation

Precision medicine is a prototype in healthcare which provides the customization of healthcare with medical decisions, practices, treatments, and products for patients in person. It states about right therapeutic approach for the right patient at the right time. The use of precision medicine is to identify which treatment approach is effective for patients on the basis of genetic, environment, and lifestyle factors. Precision medicine software allows the healthcare professionals (HCPs) to provide personalized treatment plans to patients based on their genetic content. It gives a wide range of applications in both the clinical and diagnostic areas and it combines genetic and clinical data to cater targeted patient care, which is increasing the demand of precision medicine software market.

Request a [emailprotected] https://www.absolutemarketsinsights.com/request_sample.php?id=349

The global precision medicine software market is experiencing lucrative growth owing to the increase in the number of patients suffering from chronic diseases such as cancer, heart diseases, and diabetes. For instance, as per the data presented by International Agency for Research on Cancer (IARC), in 2018, the cancer burden was 18.1 million new cases and 9.6 million deaths across the world. One in five men and one in six women around the globe develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease.

Koninklijke Philips N.V. (Philips Healthcare), a multinational electronics company focusing on healthcare, offers precision medicine platform, namely, IntelliSpace. It enables end-to-end oncology care or cancer management. The platform unifies and streamlines oncology care throughout the patient journey from molecular diagnostics to therapy recommendations. IntelliSpace, a precision medicine oncology solution integrates information over different clinical domains such as pathology, electronic health record (EHR) systems, radiology, and genomics. It consolidates all key patient and medical data in one location to represent a clear, comprehensible view of patient status in its disease and enable data driven clinical decision support, which in turn is propelling the precision medicine software market.

Enquiry Before [emailprotected] https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=349

Precision medicine with the integration of artificial intelligence (AI) will go to the next level with more accuracy and prediction of outcome for patients. Its major benefit for precision medicine is that it predicts outcomes as well as enables healthcare professionals to predict patients probability of having diseases in the future, thus driving the demand of precision medicine software market. Oracle, an American multinational computer technology corporation offers precision medicine software that enables researchers, clinicians, and molecular pathologists to work together. The software addresses data aggregation, normalization and workflow issues, knowledge exchange which restricts timely creation of patient molecular profiles and it also enables spectrum testing from gene panels through whole genome sequencing, and integration with electronic health record systems for seamless clinical workflow.

The detailed research study provides qualitative and quantitative analysis of the global precision medicine software market. The precision medicine software market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Request for [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=349

Key Findings of the Report:

Global Precision Medicine Software Market

Get Full Information of this premium [emailprotected] https://www.absolutemarketsinsights.com/reports/Precision-Medicine-Software-Market-2019-2027-349

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights

Email id: [emailprotected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

The Work Lab,

Model Colony, Shivajinagar, Pune, MH, 411016

Website: https://www.absolutemarketsinsights.com/

Continue reading here:
Astonishing growth in Precision Medicine Software Market is expected to grow at CAGR 12.3% from 2019 to 2027 - Crypto Daily

Americans encounter some form of artificial intelligence and machine learning technologies in nearly every aspect of daily life: We accept Netflixs recommendations on what movie we should stream next, enjoy Spotifys curated playlists and take a detour when Waze tells us we can shave eight minutes off of our commute.

And it turns out that were fairly comfortable with this new normal: A survey released last year by Innovative Technology Solutions found that, on a scale of 1 to 10, Americans give their GPS systems an 8.1 trust and satisfaction score, followed closely by a 7.5 for TV and movie streaming services.

But when it comes to higher stakes, were not so trusting. When asked about whether they trust an AI doctor diagnosing or treating a medical issue, respondents scored it just a 5.4.

CMS Doubles Down on CAHPS and Raises the Bar on Member Experience

A new CMS final rule will double the impact of CAHPS and member experience on a Medicare plans overall Star Rating. Learn more and discover how to exceed member expectations and improve Star Ratings in this new whitepaper.

Overall skepticism about medical AI and ML is nothing new. In 2012, we were told that IBMs AI-powered Watson was being trained to recommend treatments for cancer patients. There were claims that the advanced technology could make medicine personalized and tailored to millions of people living with cancer. But in 2018, reports surfaced that indicated the research and technology had fallen short of expectations, leaving users to speculate the accuracy of Watsons predictive analytics.

RELATED:Investors poured $4B into healthcare AI startups in 2019

Patients have been reluctant to trust medical AI and ML out of fear that the technology would not offer a unique or personalized recommendation based on individual needs. A piece in Harvard Business Review in 2019 referenced a survey in which 200 business students were asked to take a free health assessment to perform a diagnosis40% of students signed up for the assessment when told their doctor would perform the diagnosis, while only 26% signed up when told a computer would perform the diagnosis.

These concerns are not without basis. Many of the AI and ML approaches that are being used in healthcare todaydue to simplicity and ease of implementationstrive for performance at the population-level by fitting to the characteristics most common among patients. They look to do well in the general case, failing to serve large groups of patients and individuals with unique health needs. However, this limitation of how AI and ML is being applied is not a limitation of the technology.

If anything, what makes AI and ML exceptionalif done rightis its ability to process huge sets of data comprising a diversity of patients, providers, diseases and outcomes and model the fine-grained trends that could potentially have a lasting impact on a patients diagnosis or treatment options. This ability to use data in the large for representative populations and to obtain inferences in the small for individual-level decision support is the promise of AI and ML. The whole process might sound impersonal or cookie-cutter, but the reality is that the advancements in precision medicine and delivery will make care decisions more data-driven and thus more exact.

Consider a patient choosing a specialist. Its anything but data-driven: Theyll search for a provider in-network or maybe one that is conveniently located, without understanding potential health outcomes as a result of their choice. The issue is that patients lack the proper data and information they need to make these informed choices.

RELATED:The unexpected ways AI is impacting the delivery of care, including for COVID-19

Thats where machine intelligence comes into playan AI/ML model that is able to accurately predict the right treatment, at the right time, by the right provider for a patient, which could drastically help reduce the rate of hospitalizations and emergency room visits.

As an example, research published last month in AJMC looked at claims data from 2 million Medicare beneficiaries between 2017 and 2019 to evaluate the utility of ML in the management of severe respiratory infections in community and post-acute settings. The researchers found that machine intelligence for precision navigation could be used to mitigate infection rates in the post-acute care setting.

Specifically, at-risk individuals who received care at skilled nursing facilities (SNFs) that the technology predicted would be the best choice for them had a relative reduction of 37% for emergent care and 36% for inpatient hospitalizations due to respiratory infections compared to those who received care at non-recommended SNFs.

This advanced technology has the ability to comb through and analyze an individuals treatment needs and medical history so that the most accurate recommendations can be made based on that individuals personalized needs and the doctors or facilities available to them. In turn, matching a patient to the optimal provider has the ability to drastically improve health outcomes while also lowering the cost of care.

We now have the technology where we can use machine intelligence to optimize some of the most important decisions in healthcare. The data show results we can trust.

Zeeshan Syed is the CEO and Zahoor Elahi is the COO of Health at Scale.

Read more from the original source:
Industry VoicesAI doesn't have to replace doctors to produce better health outcomes - FierceHealthcare